NEW
YORK, June 18, 2024 /PRNewswire/ -- The
global female sexual dysfunction treatment market size is estimated
to grow by USD 21.69 billion from
2024-2028, according to Technavio. The market is estimated to grow
at a CAGR of about 51.9% during the forecast period.
Increasing prevalence of chronic diseases is driving market
growth, with a trend towards increasing R and
D for treatment of sexual dysfunction in women.
However, adverse effects of drugs used in female sexual
dysfunction treatment poses a challenge. Key market players
include Assos Ilac, Cipla Inc., DARE BIOSCIENCE INC., Dr Reddys
Laboratories Ltd., Duchesnay Inc., Endo International Plc, Freya
Pharma Solutions B.V., Lupin Ltd., Mithra Pharmaceuticals SA, Novo
Nordisk AS, Palatin Technologies Inc., Pfizer Inc., Pharmbio Korea
Inc., Sprout Pharmaceuticals Inc., Strategic Science and
Technologies LLC, Teva Pharmaceutical Industries Ltd., and Viatris
Inc..
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the snapshot
of this report
Female Sexual
Dysfunction Treatment Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Decelerate at a CAGR of
51.9%
|
Market growth
2024-2028
|
USD 21691.6
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
36.97
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
61%
|
Key
countries
|
US, Canada, Germany,
UK, and France
|
Key companies
profiled
|
Assos Ilac, Cipla Inc.,
DARE BIOSCIENCE INC., Dr Reddys Laboratories Ltd., Duchesnay Inc.,
Endo International Plc, Freya Pharma Solutions B.V., Lupin Ltd.,
Mithra Pharmaceuticals SA, Novo Nordisk AS, Palatin Technologies
Inc., Pfizer Inc., Pharmbio Korea Inc., Sprout Pharmaceuticals
Inc., Strategic Science and Technologies LLC, Teva Pharmaceutical
Industries Ltd., and Viatris Inc.
|
Market Driver
The female sexual dysfunction treatment market is experiencing
substantial growth due to intensive research and development
(R&D) in this area. This investment is leading to improved
diagnostic tools, personalized treatment approaches, and rigorous
clinical trials. For instance, Dare Bioscience and Strategic
Science and Technologies have initiated a study to validate
patient-reported outcome measures for assessing the efficacy of
Sildenafil Cream in women with sexual arousal disorder. These
efforts are ensuring evidence-based medicine and optimizing
treatment outcomes.
The market for female sexual dysfunction treatments is
experiencing significant growth. Companies are developing new
technologies and therapies to address conditions such as low
libido, dyspareunia, and vaginal atrophy. These conditions can
impact a woman's quality of life and relationships. Treatments
include hormone therapy, device-based therapies, and behavioral
therapies. Hormone therapy can help alleviate vaginal dryness and
discomfort. Device-based therapies, such as vaginal dilators, can
help improve sexual function. Behavioral therapies, like sex
education and counseling, can help improve communication and reduce
anxiety. The market is expected to continue growing as more women
seek effective treatments for these conditions. Companies are
investing in research and development to bring innovative solutions
to market.
Research report provides comprehensive data on
impact of trend. For more details- Download a Sample
Report
Market Challenges
- The Female Sexual Dysfunction Treatment Market encompasses
various options, including hormonal therapy and medications.
Hormonal therapy involves estrogen and androgen, which carry risks
such as breast and ovarian cancer, stroke, and vision loss.
Osphena, an estrogen agonist, can lead to cardiovascular disorders
and malignant neoplasms. Its clinical trials reported stroke
incidence rates of 0.72 and 1.45 per 1,000 women, respectively.
Flibanserin, another medication, may cause central nervous system
depression and hypotension. These adverse effects may decrease
patient compliance, negatively impacting market growth.
- The Female Sexual Dysfunction (FSD) treatment market faces
several challenges. Key areas of concern include the high
prevalence of conditions like dyspareunia, vaginism, and hypoactive
sexual desire disorder (HSDD). These conditions impact a
significant number of women, making it essential to develop
effective treatment methods. Another challenge is the stigma
surrounding sexual health issues, which can deter women from
seeking help. Additionally, the lack of proper education and
awareness about FSD contributes to the problem. The market also
requires cost-effective and convenient treatment options, as many
women find it difficult to access specialized care. Overall,
addressing these challenges will require a multi-faceted approach,
including increased awareness, affordable treatment options, and
the development of innovative solutions.
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This female sexual dysfunction treatment market report
extensively covers market segmentation by
- Age Group
- 1.1 Above 40 years
- 1.2 Below 40 years
- Product
- 2.1 Non-hormonal therapy
- 2.2 Hormonal therapy
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Above 40 years- The Female Sexual Dysfunction
(FSD) treatment market caters to women experiencing sexual health
issues, such as low libido, vaginal dryness, and difficulty
achieving orgasm. Market growth is driven by increasing awareness,
rising prevalence, and advancements in treatment options. These
include hormone therapy, pharmaceuticals, and non-invasive
therapies. Companies are investing in research and development to
offer effective and accessible solutions, meeting the unmet needs
of this significant population.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2017-2021) - Download a Sample Report
Research Analysis
The Female Sexual Dysfunction (FSD) Treatment Market encompasses
various interventions for managing sexual health issues among
women, including chronic diseases such as Diabetes and
Cardiovascular Diseases. This market caters to the needs of
menopausal women experiencing hormonal changes and Gynecological
Disorders, which may impact their Sexual Response. Stress and
Anxiety, Depression, and Interpersonal Difficulties are common
psychological factors contributing to FSD. Treatment modalities
include Psychotherapy, Hormonal Therapy, and Medications like
Phosphodiesterase Inhibitors. Pelvic Floor Exercises are also
recommended for improving sexual function. The market aims to
address various aspects of FSD, including low Sexual Desire,
Arousal Disorders, and Orgasmic Dysfunction. Chronic Disorders,
such as Cancer and Cardiovascular Disorders, may also impact sexual
health, necessitating specialized treatments.
Market Research Overview
The Female Sexual Dysfunction (FSD) treatment market encompasses
various therapies and approaches aimed at addressing sexual health
concerns in women. These issues can include decreased sexual
desire, arousal disorders, orgasmic dysfunction, and pain during
intercourse. Treatment modalities range from pharmacological
interventions, such as selective estrogen receptor modulators and
phosphodiesterase inhibitors, to psychotherapeutic approaches,
including sex therapy and cognitive-behavioral techniques.
Additionally, alternative therapies like acupuncture, herbal
remedies, and mindfulness practices are gaining popularity in the
FSD treatment landscape. Overall, the market prioritizes
evidence-based, patient-centered solutions to improve women's
sexual well-being and satisfaction.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Age Group
-
- Above 40 Years
- Below 40 Years
- Product
-
- Non-hormonal Therapy
- Hormonal Therapy
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/female-sexual-dysfunction-treatment-market-size-is-set-to-grow-by-usd-21-69-billion-from-2024-2028--increasing-prevalence-of-chronic-diseases-boost-the-market-technavio-302174093.html
SOURCE Technavio